4Filing Date: Apr 3, 2026

Metlife 4: Johnson Jeh C. bought 721 shares of Common Stock at $71.17… (Apr 3, 2026)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001707516-26-000007
Total Value$51.3K
Trades1
Insiders1

Transaction Details

Johnson Jeh C.
Director·Direct
Grant · Acquire
Common Stock
Shares+721
Price$71.17
Total Value$51.3K
Shares Owned After8.85K
Transaction DateApr 1, 2026
Footnotes ▸

MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Post-Transaction Holdings

Johnson Jeh C. · Director
SecuritySharesChange
Common Stock8.85K+721 (8.87%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-04-01 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: METLIFE INC (MET) CIK: 0001099219 --- Reporting Owner --- Name: Johnson Jeh C. CIK: 0001707516 Role: Director --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-04-01 | Code: A (Grant or award) Shares: +721 | Price: $71.17 Total Value: $51,313.57 Shares Owned After: 8,850 | Ownership: D (Direct) Footnotes: [F1] MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. --- Footnotes (Complete Index) --- F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. --- Signature --- /s/ /s/ Taylor McInerney Jansen, Attorney-in-fact (2026-04-03)

keid analysis is for reference only and does not constitute investment advice.